Paul Melmeyer

Oct 28, 2024 | neurologylive.com | Paul Melmeyer

CommentaryVideoOctober 28, 2024Author(s):Fact checked by:,Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases. “The field is learning at lightspeed pace about gene therapies...

Oct 10, 2024 | cgtlive.com | Paul Melmeyer |Noah Stansfield

The Muscular Dystrophy Association (MDA) will be holding its next Clinical & Scientific Conference on March 16-19, 2025, in Dallas, Texas. In the anticipation of this, CGTLive® reached out to Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA, to get his view on what to look forward to at the upcoming meeting. Melmeyer explained what MDA and the conference are and how they serve the neuoromuscular disease community.

Oct 8, 2024 | cgtlive.com | Paul Melmeyer |Noah Stansfield

“The field is learning at lightspeed pace about gene therapies...

Feb 29, 2024 | cgtlive.com | Paul Melmeyer

This content originally appeared on our sister site, NeurologyLive®. "This isn't just one day's effort or one week's effort or even just one month's effort. This is a constant effort that we, in the neuromuscular disease community, are trying to move forward."Rare Disease Day is an annual event, held this year on February 29, focused on raising awareness and understanding for the millions of patients worldwide living with rare disorders.

Feb 29, 2024 | neurologylive.com | Paul Melmeyer

February 29, 2024In honor of Rare Disease Day, the vice president of public policy and advocacy at the Muscular Dystrophy Association shared his perspective of advocacy and policy progress in the realm of rare neuromuscular diseases. [WATCH TIME: 6 minutes]WATCH TIME: 6 minutes"This isn't just one day's effort or one week's effort or even just one month's effort.